2 FTSE 100 stars you should consider buying before it’s too late

Royston Wild looks at two Footsie giants that could be about to explode.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

To say that 2016 has proved to be a horror show for the ITV (LSE: ITV) share price would be putting it a little lightly.

The broadcasting giant has seen the value of its stock erode 36% since the year kicked off, the company even taking in three-year troughs in the days following June’s shock EU referendum result.

The evaporation in investor appetite can be considered wholly justified on one hand, reflecting a marked slowdown in advertising revenues at the company. Just this month ITV advised that ad sales fell 4% during the July to September quarter. Has trade improved since? No chance. The business also advised that “in recent weeks the political and economic uncertainty has increased and we are currently seeing more cautious behaviour by advertisers.”

And the TV firm suggested that there’s worse to come as Brexit dominates commercial decisions — as a result, ITV has pencilled-in a 7% earnings dip for the fourth quarter.

Of course waning advertiser revenues are a big problem for the broadcaster, but stock pickers shouldn’t overlook the robust performance of the rest of the business. ITV announced that revenues from its ITV Studios production arm soared 18% during Q3, to £923m, reflecting the media firm’s ambitious global expansion drive.

On top of this, ITV’s Online, Pay & Interactive division enjoyed a 22% revenues uptick during the last quarter, demonstrating the company’s know-how across media platforms.

So although ITV’s brilliant record of earnings generation is expected to come to a halt in 2016 — a 1% drop is anticipated by City analysts — I reckon a consequent P/E rating of 10.1 times is a supreme level at which to latch onto the firm’s stunning long-term growth prospects.

Meanwhile, a 4.4% dividend yield also suggests ITV is currently undervalued by the market.

The right medicine

There’s also an argument that recent heavy selling at GlaxoSmithKline (LSE: GSK) is somewhat unjustified given the pharma ace’s rapidly-improving sales outlook.

After reaching record peaks above £17.20 per share in October, GlaxoSmithKline has seen investor demand cool sharply during the last six weeks and the firm was most recently dealing at a hefty 12% discount to last month’s heights.

However, I’m convinced GlaxoSmithKline’s next charge higher is a matter of ‘when’ rather than ‘if’. Why? An anticipated 31% earnings rise in 2016 should herald an end to the value-crushing patent problems of yesteryear.

Indeed, the pills play’s rejuvenated product pipeline looks set to supercharge group revenues in the years ahead, particularly as GlaxoSmithKline pours huge investment into fast-growing areas like HIV and vaccines.

And the Brentford-based business certainly offers excellent value for money given its blockbuster investment potential. GlaxoSmithKline boasts a forward P/E ratio of 15.1 times, in line with the wider FTSE 100 average. But a 5.3% dividend yield takes the scythe to most of the Footsie competition.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended ITV. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

1 discounted US stock for me to buy for the cybersecurity revolution!

This AI-powered cybersecurity company's beating its rival technologies, and a recent share price drop may have just created a buying…

Read more »

Investing Articles

Buying 1,019 shares of this FTSE 100 monopoly could earn me £2,284 in passive income

National Grid’s monopoly status makes it a popular passive income stock. But investors shouldn’t underestimate the risks that come with…

Read more »

Investing Articles

£5k in savings? Here’s how I’d aim to build a rising passive income of £5,500 a month

Harvey Jones invests in FTSE 100 dividend stocks with the aim of generating a growing passive income to fund his…

Read more »

Investing Articles

Are these 2 legendary dividend stocks worth buying and holding until 2030?

Zaven Boyrazian explores two of the UK's most legendary dividend stocks with tremendous track records. But are they good long-term…

Read more »

Investing Articles

I’d listen to Warren Buffett’s advice and buy undervalued shares today

Warren Buffett’s focus on quality at a reasonable price has proven to be a highly lucrative strategy that other investors…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

How I’d aim to turn an empty ISA into a £50k second income!

Zaven Boyrazian outlines how investors can target a £50,000 second income starting with a brand new ISA while also keeping…

Read more »

Investing Articles

Up 202%! This hidden FTSE gem has outpaced the Rolls-Royce share price and is still climbing!

The Rolls-Royce share price may have outpaced every FTSE 100 rival over the last couple of years but Harvey Jones…

Read more »

Investing Articles

How I’d invest my first £1,000 in a SIPP

Investing the first £1,000 in an SIPP can be a daunting process, especially for new investors. Zaven Boyrazian explains what…

Read more »